Amgen Reaches New 52-Week High at $132.52 (AMGN)
Amgen (NASDAQ:AMGN) reached a new 52-week high on Thursday , Analyst Ratings Network.com reports. The company traded as high as $132.52 and last traded at $131.76, with a volume of 4,380,578 shares. The stock had previously closed at $127.34.
AMGN has been the subject of a number of recent research reports. Analysts at Argus reiterated a “buy” rating on shares of Amgen in a research note on Monday, August 4th. They now have a $140.00 price target on the stock, up previously from $135.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Amgen in a research note on Thursday, July 31st. They now have a $137.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Amgen from $135.00 to $140.00 in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Amgen has a consensus rating of “Buy” and a consensus target price of $139.44.
The stock’s 50-day moving average is $122.2 and its 200-day moving average is $119.4. The company has a market cap of $100.2 billion and a price-to-earnings ratio of 19.50. Amgen also saw unusually large options trading activity on Monday. Investors acquired 23,340 call options on the stock. This represents an increase of approximately 292% compared to the average volume of 5,961 call options.
Amgen (NASDAQ:AMGN) last released its earnings data on Tuesday, July 29th. The company reported $2.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.07 by $0.30. The company had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. Analysts expect that Amgen will post $8.38 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 5th. Stockholders of record on Thursday, August 14th will be given a dividend of $0.61 per share. This represents a $2.44 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend is Tuesday, August 12th.
In other Amgen news, EVP Sean E. Harper sold 14,000 shares of the stock on the open market in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $127.29, for a total value of $1,782,060.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.